CAR T cell therapy candidate will be evaluated in Phase I multicenter, open-label clinical trial.
Adicet Bio has announced that the FDA has cleared its Investigational New Drug (IND) application to evaluate ADI-270, an armored allogeneic “off-the-shelf” gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70+ cancers, for the treatment of relapsed/refractory renal cell carcinoma (RCC). Adicet plans to initiate a Phase I clinical trial to assess the safety and anti-tumor activity of ADI-270 in RCC patients later this year.1
The future study evaluating ADI-270 will be a Phase I multicenter, open-label clinical trial that is designed to investigate ADI-270 as monotherapy in adults with relapsed or refractory clear cell RCC. Following lymphodepletion, patients will be eligible to receive a single dose of ADI-270 with a starting dose level of 3E8 CAR+ cells. The trial is set to have dose escalation and dose expansion phases.
According to the American Cancer Society, kidney cancer is one of the 10 most common cancers in both men and women in the United States. In 2024, approximately 81,610 new cases of kidney cancer (52,380 in men and 29,230 in women) will be diagnosed.2
“ADI-270 is the first ever gamma delta 1 CAR T cell therapy candidate to enter clinical trials for the treatment of solid tumors,” Chen Schor, president and CEO of Adicet Bio said in a press release. “The FDA’s clearance of our IND application to evaluate ADI-270 in patients with RCC underscores a significant achievement for Adicet. ADI-270 is a third-generation CAR T designed to target CD70+ tumors with high specificity, increased exposure, persistence and tumor infiltration, while addressing immunosuppressive factors in the tumor microenvironment. RCC is the most common type of kidney cancer and has a high unmet need with limited viable treatment options available. With its highly differentiated profile, we believe that ADI-270 has the potential to become an important therapeutic option for patients with RCC and other CD70+ tumors.”
Earlier in April, Adicet shared preclinical data that showed anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models.3
According to Adicet, the findings included:
1. Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma. Adicet Bio. News release. June 24, 2024. Accessed June 25, 2024. https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-announces-fda-clearance-ind-application-adi-270-renal
2. Key Statistics About Kidney Cancer. American Cancer Society. May 1, 2024. Accessed June 25, 2024. https://www.cancer.org/cancer/types/kidney-cancer/about/key-statistics.html
3. Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting. Adicet Bio. News release. April 22, 2024. Accessed June 25, 2024. https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-highlights-preclinical-data-supporting-ind-readiness
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.